| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $14.1M | -94.6% | -35.2% |
| SG&A Expense | $14.0M | +9.2% | +108.6% |
| Operating Income | -$28.1M | +89.8% | +1.4% |
| Net Income | -$812.7M | +48.4% | -2848.9% |
| EPS (Basic) | -$121.63 | -868.4% | — |
| EPS (Diluted) | -$121.63 | -868.4% | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $160.5M | -15.8% | +203.9% |
| Short-term Investments | $10.0M | +0.1% | -0.1% |
| Current Assets | $172.5M | -15.8% | +156.3% |
| Total Assets | $176.2M | -14.2% | +51.9% |
| Current Liabilities | $18.8M | -67.9% | +31.3% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$119.9M | — | — |
| Capital Expenditures | $627K | — | — |
| Investing Cash Flow | $172K | — | — |
| Financing Cash Flow | $196.0M | — | — |
| Free Cash Flow | -$120.5M | — | — |
| $2.40B |
| +40.4% |
| +5480.7% |
| Stockholders' Equity | -$2.23B | -47.8% | -3150.5% |